Close

Brainstorm Cell Therapeutics (BCLI) Sets Date to Announce Top-Line NurOwn Phase 2 Data in ALS Patients

July 14, 2016 3:31 PM EDT Send to a Friend
BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login